Cellivate Technologies, a promising biotech startup, has successfully raised $1 million in a seed funding round led by Antler, with additional participation from Venture Catalysts, Hatcher+, and We Founder Circle. The newly acquired funds will be instrumental in accelerating the company’s research and development (R&D) efforts, scaling up production, and expanding its market reach, according to a press release from Cellivate.
Launched by Viknish Krishnan Kutty, Cellivate Technologies is at the forefront of innovation in cell culture and biomanufacturing. The company is focused on addressing critical challenges in these fields through the development of advanced solutions. Its flagship products include innovative microcarriers designed to enhance cell growth and a novel cell-based serum intended to replace fetal bovine serum (FBS) in cell culture.
With the cell culture market, particularly the segments involving microcarriers and serum, projected to reach $33 billion by 2030, Cellivate Technologies is positioning itself to become a key player in this rapidly growing industry.
Cellivate’s innovative products are designed not only to boost efficiency and reduce costs but also to address ethical concerns associated with traditional cell culture methods. The company emphasizes that its advancements could significantly reduce society’s dependence on animal slaughter, as products and ingredients conventionally derived from animals can now be procured from cells.
The funding will enable Cellivate to further its R&D activities, scale up the production of its microcarriers and cell-based serum, and expand its footprint in the market. The company’s efforts are in line with the growing demand for more sustainable and ethical solutions in biotechnology.